These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37663730)

  • 1. Recombinant anti-human epidermal growth factor receptor type 2 single-chain variable fragment-alpha-luffin fusion protein as a putative immunotoxin against human epidermal growth factor receptor type 2-positive breast cancer cells: an experimental research.
    Damough S; Bayat E; Oghabi Bakhshaiesh T; Barkhordari F; Esmaeili R; Nematollahi L; Talebkhan Y
    Ann Med Surg (Lond); 2023 Sep; 85(9):4348-4354. PubMed ID: 37663730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion.
    Park S; Nguyen MQ; Ta HKK; Nguyen MT; Lee G; Kim CJ; Jang YJ; Choe H
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel EGFR-specific recombinant ricin-panitumumab (scFv) immunotoxin against breast and colorectal cancer cell lines; in silico and in vitro analyses.
    Naemi AA; Salmanian AH; Noormohammadi Z; Amani J
    Eur J Pharmacol; 2023 Sep; 955():175894. PubMed ID: 37429519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and construction of scFv-PE35KDEL as a novel immunotoxin against human epidermal growth factor receptor 2 for cancer therapy.
    Shariaty Vaziri Z; Shafiee F; Akbari V
    Biotechnol Lett; 2023 Apr; 45(4):537-550. PubMed ID: 36807722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; High in vitro anti-cancer potency.
    Rezaie E; Amani J; Bidmeshki Pour A; Mahmoodzadeh Hosseini H
    Eur J Pharmacol; 2020 Mar; 870():172912. PubMed ID: 31926992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crotamine-based recombinant immunotoxin targeting HER2 for enhanced cancer cell specificity and cytotoxicity.
    Jang J; Nguyen MQ; Park S; Ryu D; Park H; Lee G; Kim CJ; Jang YJ; Choe H
    Toxicon; 2023 Jul; 230():107157. PubMed ID: 37196787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cloning, expression and characterization of a HER2-alpha luffin fusion protein in
    Barkhordari F; Sohrabi N; Davami F; Mahboudi F; Garoosi YT
    Prep Biochem Biotechnol; 2019; 49(8):759-766. PubMed ID: 31032734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and antitumor effect of a toxin-linked conjugate targeting vascular endothelial growth factor receptor and urokinase plasminogen activator.
    Xiang Y; Li Q; Huang D; Tang X; Wang L; Shi Y; Zhang W; Yang T; Xiao C; Wang J
    Exp Biol Med (Maywood); 2015 Feb; 240(2):160-8. PubMed ID: 25125500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and characterization of a recombinant immunotoxin for targeted therapy of breast cancer cells: In vitro and in silico analyses.
    Barazesh M; Mohammadi S; Jalili S; Kavousipour S; Faraji SN; Mokarram P; Pirhadi S
    Life Sci; 2021 Jan; 265():118866. PubMed ID: 33301810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin.
    Zhou X; Qiu J; Wang Z; Huang N; Li X; Li Q; Zhang Y; Zhao C; Luo C; Zhang N; Teng X; Chen Z; Liu X; Yu X; Wu W; Wei YQ; Li J
    J Cancer Res Clin Oncol; 2012 Jul; 138(7):1081-90. PubMed ID: 22392077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Manufacture and evaluation of a HER2-positive breast cancer immunotoxin 4D5Fv-PE25.
    Peng Y; Wu Z; Pang Z; Zhang L; Song D; Liu F; Li Y; Lin T
    Microb Cell Fact; 2023 May; 22(1):100. PubMed ID: 37198642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Targeted detecting HER2 expression with recombinant anti HER2 ScFv-GFP fusion antibody].
    Gao G; Chen C; Yang Y; Yang H; Wang J; Zheng Y; Huang Q; Hu X
    Sheng Wu Gong Cheng Xue Bao; 2012 Aug; 28(8):1002-14. PubMed ID: 23185900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen binding and cytotoxic properties of a recombinant immunotoxin incorporating the lytic peptide, melittin.
    Dunn RD; Weston KM; Longhurst TJ; Lilley GG; Rivett DE; Hudson PJ; Raison RL
    Immunotechnology; 1996 Sep; 2(3):229-40. PubMed ID: 9373315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A chemical conjugate between HER2-targeting antibody fragment and Pseudomonas exotoxin A fragment demonstrates cytotoxic effects on HER2-expressing breast cancer cells.
    Lee S; Park S; Nguyen MT; Lee E; Kim J; Baek S; Kim CJ; Jang YJ; Choe H
    BMB Rep; 2019 Aug; 52(8):496-501. PubMed ID: 30670149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.
    Bruell D; Bruns CJ; Yezhelyev M; Huhn M; Müller J; Ischenko I; Fischer R; Finnern R; Jauch KW; Barth S
    Int J Mol Med; 2005 Feb; 15(2):305-13. PubMed ID: 15647848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Hydra HALT-1 as a toxin moiety for recombinant immunotoxin.
    Jiemy WF; Hiew LF; Sha HX; In LLA; Hwang JS
    BMC Biotechnol; 2020 Jun; 20(1):31. PubMed ID: 32552895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer.
    Simon N; Antignani A; Sarnovsky R; Hewitt SM; FitzGerald D
    J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27075852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiproliferative and apoptotic effects of a specific anti-insulin-like growth factor I receptor single chain antibody on breast cancer cells.
    Motallebnezhad M; Younesi V; Aghebati-Maleki L; Nickho H; Safarzadeh E; Ahmadi M; Movassaghpour AA; Hosseini A; Yousefi M
    Tumour Biol; 2016 Nov; 37(11):14841-14850. PubMed ID: 27639384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction and characterization of the recombinant immunotoxin RTA-4D5-KDEL targeting HER2/neu-positive cancer cells and locating the endoplasmic reticulum.
    Jiao P; Zhang J; Dong Y; Wei D; Ren Y
    Appl Microbiol Biotechnol; 2018 Nov; 102(22):9585-9594. PubMed ID: 30141083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and construction of a recombinant lentiviral vector with specific tropism to human epidermal growth factor-overexpressed cancer cells: Developing a new retargeting system for lentivirus vectors.
    Ebrahimabadi S; Shahbazi M; Akbari M; Golalipour M; Farazmandfar T
    J Gene Med; 2019 Jun; 21(6):e3095. PubMed ID: 31050357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.